- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 72
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more
Location Directory
Clinical trials in Dallas, Texas
This page shows live ClinicalTrials.gov search results for Dallas, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
13791
Shown on this page
12
Current sort
Recently updated
Location scope
Dallas, TX
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 577–588 of 13,791 matching trials in Dallas, TX.
Live ClinicalTrials.gov results.
Institutions in Dallas
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 935 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 35 more
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- TAR-200, Mitomycin C, Gemcitabine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 29
- States / cities
- Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 24 more
- Conditions
- Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
- Interventions
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 791
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 512 more
- Conditions
- Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
- Interventions
- Rina-S, IC
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 69
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Irvine, California + 51 more
- Conditions
- High-Risk Neuroblastoma
- Interventions
- hu1418K322A + Temozolomide + Irinotecan
- Drug
- Lead sponsor
- Renaissance Pharma Ltd.
- Industry
- Eligibility
- 18 Months to 18 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 8
- States / cities
- San Francisco, California • Aurora, Colorado • Chicago, Illinois + 5 more
- Conditions
- Advanced Solid Tumors, Colorectal Cancer (CRC), Non-Small Cell Lung Cancer, Uterine Cancer, KRAS G12C Mutations, KRAS G12S Mutations
- Interventions
- KQB368
- Drug
- Lead sponsor
- Kumquat Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 11 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Teclistamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 587 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Duarte, California • Stanford, California + 14 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
- Interventions
- Pembrolizumab, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, Biopsy, Questionnaire Administration
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2037
- U.S. locations
- 429
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 340 more
- Conditions
- Ovarian Cancer, Non-small Cell Lung Cancer
- Interventions
- TUB-040, Bevacizumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 10 more
- Conditions
- Arthritis, Psoriatic
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 50
- States / cities
- Mountain Brook, Alabama • Avondale, Arizona • Flagstaff, Arizona + 46 more
- Conditions
- Atopic Dermatitis
- Interventions
- APG777, Placebo
- Drug
- Lead sponsor
- Apogee Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 29
- States / cities
- Fountain Valley, California • Los Angeles, California • San Diego, California + 25 more